# INSIGHT-IBD Pragmatic Study

> **NCT07686757** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Specialty Networks Research.** · enrollment: 400 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)
- Crohn Disease (CD)

## Interventions

- **DRUG:** Mirikizumab
- **DRUG:** Anti-TNF agents
- **DRUG:** anti-integrin antibodies
- **DRUG:** IL-12
- **DRUG:** IL-23

## Key facts

- **NCT ID:** NCT07686757
- **Lead sponsor:** Specialty Networks Research.
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-08-12
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686757, "INSIGHT-IBD Pragmatic Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07686757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*